The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 5mg×5 Compared With Lamotrigine Compressed Tablet 25mg in Chinese Healthy Male Subjects
Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Epilepsy
Intervention: Lamotrigine Dispersible/Chewable tablets 5mg*5 (Drug); Lamotrigine Compressed tablet 25mg (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: GlaxoSmithKline Official(s) and/or principal investigator(s): GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline
Summary
This is a single dose, open-label, randomized, two-period crossover study to demonstrate the
bioequivalence of lamotrigine dispersible/chewable tablets (5mg×5) and lamotrigine
compressed tablets (25mg) in healthy Chinese male subjects in fasting conditions. The
safety, tolerability and pharmacokinetic profile of lamotrigine dispersible/chewable tablets
will also be assessed.
Clinical Details
Official title: A Single-Dose, Open-Label, Randomized, Two-Period Crossover Study to Demonstrate the Bioequivalence of Lamotrigine Dispersible/Chewable Tablets (5mg×5) and Lamotrigine Compressed Tablet (25mg) in Healthy Chinese Male Subjects.
Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Area under the concentration-time curve from time zero to infinity [AUC(0-inf)], including bioequivalence evaluationArea under the concentration-time curve up to the last time point at which the concentration is above the lower limit of quantification [AUC(0-t)], including bioequivalence evaluation The observed maximum serum drug concentration (Cmax), including bioequivalence evaluation
Secondary outcome: Time to reach Cmax (tmax)Elimination half-time (t½) Elimination rate constant, linear regression according to linear serum drug concentration-time curve
Detailed description:
This is a single dose, open-label, randomized, two-period crossover study to demonstrate the
bioequivalence of lamotrigine dispersible/chewable tablets (5mg×5) and lamotrigine
compressed tablets (25mg) in healthy Chinese male subjects in fasting conditions. 24 healthy
Chinese male subjects will be enrolled to provide data from at least 22 evaluable subjects .
In Period 1, subjects will be randomized in equal numbers to be dosed with either
lamotrigine dispersible/chewable 5mg×5 tablets or lamotrigine compressed tablet 25mg×1.
Following a washout of at least 14 days, subjects will be crossed over in Period 2 to
receive the treatment that they did not receive in Period 1.
Pharmacokinetic blood samples will be collected over 168 hours post dose. Venous blood (2 ml
each) is taken immediately before dosing (pre-dose) and 0. 5, 1, 1. 5, 2, 2. 5, 3, 4, 6, 8, 12,
24, 36, 48, 72, 96, 120, 144 and 168 hours post dose to determine the lamotrigine
concentration in serum. Drug concentration in serum at different time points will be
determined for each subject with a validated bioanalytical method using LC/MS/MS method. The
main pharmacokinetic parameters such as Cmax, tmax, AUC(0-inf), AUC(0-t), t1/2, λz, CL/F and
Vd/F are calculated for subjects using non-compartment analysis method.
Physical examination, electrocardiogram and clinical laboratory tests are conducted at
screening and 168 hours after administration of each dose; vital signs are measured at
scheduled time; adverse events are recorded throughout the study. Clinically relevant safety
measurement values are tabulated to evaluate the safety and tolerability of lamotrigine
dispersible/chewable tablet. Safety evaluation lasts up to 168 hours after the second oral
administration.
Eligibility
Minimum age: 18 Years.
Maximum age: 40 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Healthy male non-smoker, based on medical history and physical examination.
- 18-40 years old, inclusive.
- Body weight >50 kg, and result of BMI is between 18. 0 and 24. 0 kg/m2, inclusive.
- Capable of returning to study site for follow-up according to the requirement of
protocol and willing to comply with the policy, procedure and restriction of the
study.
- Capable of reading and understanding the information listed in the consent form.
Signing the informed consent prior to any study related procedure.
- Results of laboratory tests within the range of reference normal range, or slight
abnormality which judged as not clinically significant by investigator.
- AST, ALT, alkaline phosphatase and total bilirubin =<1. 5 x ULN ((total bilirubin >1. 5
x ULN alone is acceptable if direct bilirubin <35% of total bilirubin).
- Normal blood pressure (systolic blood pressure 90-140 mmHg, diastolic blood pressure
< 90mmHg) and pulse rate (60-100/min).
- No clinically significant abnormality on 12-lead ECG.
- Corrected QT interval < 450 ms; or corrected QT interval < 480 ms for subjects with
bundle-branch block.
- Male subjects with female partners of child-bearing potential must agree to use
contraceptive method after first dose of study treatment and until two weeks after
the completion of the study.
Exclusion Criteria:
- Current or chronic history of cardiovascular, respiratory, gastrointestinal,
endocrine, hepatic, hematological, psychical or nervous system diseases, use of drug
that can change the absorption, metabolism or elimination of study drug, or result in
danger or other drugs or diseases that interfere with the interpretation of study
data.
- Personal or familial history of hypersensitivity to lamotrigine or drug with similar
chemical composition.
- Participation in other clinical trial within 30 days prior to enrollment in the
study.
- Use of prescription or non-prescription drugs, including monoamine oxidase inhibitor
or herbal drug within 14 days prior to the screening; excluding use of lubricating
oil or contraceptive barrier device containing spermicidal agents, and other
contraception device.
- History of abnormality of liver function, abnormal hepatic or biliary system, or
positive hepatitis B surface antigen (HBsAg), or positive hepatitis C surface
antibody (HCAb) or ALT ≥ 2x upper limit of normal (ULN). Having Gilbert syndrome.
- Positive serum HIV antibody.
- Alcohol abuser, defined as alcohol consumption exceeding 3 units/day or 21
units/week. A unit equal to about 240 ml beer, 25 ml spirits or 125 ml wine.
- Positive drug monitoring at screening.
- Evidence for obviously active disease of hematological system, or obvious blood loss
within 3 months.
- Blood donation 3 months prior to study.
- Current or past history of nervous-psychiatric disorder, as assessed by Columbia
Suicide Severity Rating Scale-baseline evaluation or in the opinion of investigator
that the subject is at risk of suicide or with history of suicide behavior/attempt.
- Unsuitable for participating in the study according to the law.
- Unsuitable for participating in the study in the opinion the investigator.
Locations and Contacts
GSK Investigational Site, Shanghai 200030, China
Additional Information
Starting date: April 2013
Last updated: September 5, 2013
|